DUBLIN, Apr. 21, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2013 to 2023" report to their offering.
The acquired hemophilia treatment market was valued at USD 1,923.4 Mn in 2015, and is expected to reach USD 2,474.7 Mn by 2023, expanding at a CAGR of 3.2% from 2016 to 2023.
The global acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories such as traditional therapies and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment and immunomodulatory treatment. The advanced therapies is further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA. The advanced therapies held the largest segment due to introduction of novel therapies for the treatment of acquired hemophilia.
The acquired hemophilia treatment market is observed to be majorly dominated by few players operating in the market. The market is dominated by players, depending on their major competencies. The key players in this market are Baxalta, Inc. (Shire), Novo Nordisk, Biogen, Pfizer, Inc., and F. Hoffman La Roche.
Key Market Movements:
- Acquired hemophilia represents a life threatening bleeding disorder, particularly in the geriatric population. Hence, rising geriatric population globally is a major driving factor.
- There is an increasing adoption of prophylaxis in hemophilia patients, currently standing at 25% to 30%. Thus growing demand for prophylaxis strategies would act as a driving factor in the near future.
- The key challenge faced in acquired hemophilia treatment market is limited availability and accessibility of novel drugs in the developing nations.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Global Acquired Hemophilia Treatment Market Analysis
Chapter 4 Global Acquired Hemophilia Treatment Market Analysis, By Type of Therapeutics
Chapter 5 Global Acquired Hemophilia Treatment Market, By Geography
Chapter 6 Company Profiles
- Baxalta, Inc
- Baxter Healthcare Corporation
- Bristol-Myers Squibb
- Genentech, Inc.
- Novo Nordisk A/S
- Ferring B.V.
- Sanofi SA
For more information about this report visit http://www.researchandmarkets.com/research/g9jv8j/global_acquired
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-247-billion-acquired-hemophilia-treatment-market-2023-key-players-are-baxalta-novo-nordisk-biogen-pfizer--f-hoffman-la-roche-300443485.html
SOURCE Research and Markets